Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market

You may also be interested in...



Emerging Markets Earnings Roundup: Merck And Novo Nordisk

In this earnings round up, we zoom in on Merck and Novo Nordisk’s performance in emerging markets for 2012.

Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)

In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.

Merck Doubles Down On Diabetes In China, Launches Janumet

China, home to the world’s largest diabetes population, sees another major product launch as multinationals jockey for position in the DPP-4 space in anticipation of the next NDRL revision.

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel